Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.
Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced participation in the Goldman Sachs 45th Annual Global Healthcare Conference.
CEO Pascal Touchon and EVP Cokey Nguyen will join a fireside chat on June 12, 2024, at 6:20 a.m. PDT / 9:20 a.m. EDT.
The event will be webcast live on Atara’s website, with an archived replay available for 30 days.
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at the ISCT 2024 Annual Meeting, show that ATA3219 effectively depletes CD19+ B-cells and induces lower levels of pro-inflammatory cytokines compared to autologous CD19 CAR T cells.
ATA3219 incorporates multiple clinically validated technologies, including a modified CD3ζ signaling domain and a less differentiated phenotype. A Phase 1 clinical trial for lupus nephritis (LN) and severe SLE without lymphodepletion is expected to begin in Q4 2024, with initial data anticipated in 2025.
Atara Biotherapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel (tab-cel®), targeting Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two and older.
This marks the first allogeneic T-cell therapy BLA submission for the FDA. If approved, tab-cel would be the first FDA-approved therapy for EBV+ PTLD, potentially triggering milestone payments of up to $80 million from Pierre Fabre Laboratories.
Supported by data from over 430 patients, including a 48.8% Objective Response Rate from the ALLELE study, tab-cel has shown a favorable safety profile. The BLA submission is part of a broader global partnership with Pierre Fabre, which includes double-digit tiered royalties on net sales and reimbursement for development costs.
Atara Biotherapeutics announced its first-quarter 2024 financial results and operational progress, highlighting key advancements in its lead CAR T program, ATA3219, for oncology and autoimmune diseases. The company plans to submit a BLA for tab-cel in Q2 2024 and initiate studies for lupus nephritis and non-Hodgkin’s lymphoma. Atara's cash runway extends into 2027, enabling key pipeline readouts.
Atara Biotherapeutics, Inc. granted 4,150 restricted stock units to a newly hired employee under the Nasdaq Listing Rule 5635(c)(4). The stock units vest over four years, subject to continuous employment.